Teva Faces Rocky Path to Recovery After Debt | Fortune
Allergan becomes largest shareholder in Teva - Globes
Teva collapse continues on Wall Street - Globes
Pharma Industry Champion Bloomberg: Generic Drugs Could Be Harmful - The Official Myti-Herbs Online Store
Five Considerations After Teva Pharmaceuticals' Q3 Report (NYSE:TEVA) | Seeking Alpha
Teva's Adderall Shortage Expected to Continue Into March, FDA Says - BNN Bloomberg
Building on Strong First Quarter, Teva Raises 2018 Outlook | Ctech
Teva Pharmaceuticals - Wikipedia
Teva's Working With Evercore to Review Debt Options - Bloomberg
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva, AbbVie may pay billions to settle opioid lawsuits
Teva Considers 10,000 Job Cuts - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva stock drops after conspiracy allegations on hiking drug prices
Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives | Stock News & Stock Market Analysis - IBD
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - BNN Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Says 2018 Profit Will Keep Falling as Generic Drug Slump Persists - Bloomberg
The Pharma Job From Hell: Low Salary to Fix Sinking Giant Teva - Bloomberg
Teva's CEO Was $2.8 Billion Down on His Second Day on the Job - Bloomberg
America's Most Beloved Pharmaceutical Stock Is Israel's Teva - Bloomberg
Teva's Links to Opioid Epidemic May Triple Funding Costs - Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
